Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wooyeol Baek has a total of 168 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Non-syndromic craniosynostosis: contemporary concepts in biology, diagnosis, and distraction-based operative strategy

    by Wooyeol Baek

    Non-syndromic craniosynostosis is the most common clinical form of craniosynostosis, but the mature phenotype cannot be accounted for by a purely local model of premature suture fusion. The deformity is the product of interactions among calvarial growth, cranial base geometry, dural and mesenchymal signaling, orbital development, and regional soft-tissue adaptation. This narrative review examines current evidence on epidemiology, developmental biology, diagnosis, imaging, operative timing, and surgical management, with emphasis on systematic reviews, multicenter and population-based data, comparative cohorts, and larger independent series. Contemporary options—conventional cranial vault remodeling, fronto-orbital advancement and remodeling, endoscope-assisted suturectomy with postoperative orthotic therapy, spring-assisted techniques, and distraction osteogenesis—each occupy a legitimate place in selected age groups and phenotypes. This review gives particular attention to distraction because of its potential for individualized, three-dimensional correction: it is the approach in which vector, magnitude, and regional expansion can be adjusted while new bone forms and the surrounding soft-tissue envelope adapts, which is precisely what a three-dimensional deformity demands. Current comparative evidence does not establish superiority for every subtype, but the biologic rationale and available clinical results justify a broader role for distraction in contemporary reconstruction. Osteotomy design and vector geometry should follow the dominant phenotype: transverse expansion when biparietal restriction predominates in sagittal synostosis; multivector correction when orbital, skull-base, or posterior vault distortion is established; and a higher operative threshold in metopic synostosis, where true fronto-orbital narrowing—not suture fusion alone—should drive the decision. Outcomes should be judged by deformity-specific three-dimensional balance, functional safety, treatment burden, and long-term stability, and not by a single cranial index.

  • Open Access

    Wound Healing Efficacy of Novel Dermal Substitute TissueDerm Graft® in Full-Thickness Skin Defects

    by Kyu-Sik Shim, Dohyun Kim, Jeongwoo Park, Han-Saem Jo, Nayeon Koo, Won Jai Lee, Tai Suk Roh, Wooyeol Baek

    Autologous skin grafting is considered the standard treatment for full-thickness skin defects and provides essential dermal reconstruction to support both functional and aesthetic skin outcomes. However, it has limitations, such as increased donor-site morbidity, suboptimal aesthetic outcomes, thickness mismatches, texture irregularities, and scar contractions. Several dermal substitutes have been developed to overcome these limitations. In the present study, we introduce TissueDerm Graft®, a novel collagen-based dermal substitute designed to improve both functional and aesthetic outcomes in skin grafting by providing a regular structure that supports dermal tissue regeneration. We compared the properties and efficacy of TissueDerm Graft® with those of bovine acellular dermal matrix (Matriderm®). A full-thickness skin defect was induced in minipigs and TissueDerm Graft® or Matriderm® were simultaneously transplanted with a split-thickness skin graft (STSG). In the present study, TissueDerm Graft® exhibited tightly packed and uniform collagen fibers, a consistent pore distribution, and elastin. The full-thickness skin defect model demonstrated favorable wound healing without inducing excessive inflammatory responses or excessive scar formation. Compared with the single implantation of STSG and co-implantation of STSG and Matriderm®, the co-implantation of STSG and TissueDerm Graft® improved the visual outcomes. These findings suggest that TissueDerm Graft® could serve as a promising dermal substitute for skin grafting and skin tissue regeneration.

  • Open Access

    Data from Phase IB/II Trial with Correlative Analyses of Doxorubicin plus Durvalumab Combination in Patients with Advanced Soft Tissue Sarcoma

    by Kum-Hee Yun, Nam Suk Sim, Su-Jin Shin, Young Han Lee, Wooyeol Baek, Yoon Dae Han, Ji Woo Park, Sang Kyum Kim, Iksung Cho, Inkyung Jung, et al.

    Purpose:This open-label, phase IB/II study evaluated the efficacy and safety of standard-of-care doxorubicin combined with durvalumab [a programmed death 1 ligand (PD-L1) immune checkpoint inhibitor] in patients with advanced anthracycline-naïve soft tissue sarcoma (STS) and identified patients who would most likely benefit from this combination treatment.Patients and Methods:This trial (NCT03802071) included patients with metastatic and/or recurrent STS not previously treated with anthracycline or a PD-1/PD-L1 inhibitor. Phase IB assessed the safety and tolerability of doxorubicin [level 1 (75 mg/m2); level –1 (60 mg/m2)] in combination with durvalumab 1,500 mg once every 3 weeks until documented disease progression or unacceptable toxicity. Phase II evaluated treatment efficacy, with the primary endpoint being the objective response rate (ORR).Results:As no dose-limiting toxicities were observed during the phase IB trial (n = 3), the recommended phase II dose was 75 mg/m2 of doxorubicin. Of 41 evaluable patients, 1 (2.4%) achieved a complete response and 12 (29.3%) achieved a confirmed partial response, yielding an ORR of 31.7%. Median progression-free survival (PFS) was 7.6 months, and median overall survival was 23.8 months. The most common treatment-related grade 3 to 4 adverse events were neutropenia (n = 23, 53.4%), thrombocytopenia (n = 6, 13.9%), and anemia (n = 5, 11.6%). In prespecified exploratory correlative analyses, absence of RTK–RAS pathway genetic alterations [hazard ratio (HR), 6.446; 95% confidence interval (CI), 1.934–21.486; P = 0.002] and high PD-1 expression (HR, 0.214; 95% CI, 0.071–0.649; P = 0.006) were identified as independent predictors of longer PFS.Conclusions:Doxorubicin plus durvalumab combination therapy exhibited promising efficacy in advanced STS, with acceptable toxicity profile.

  • Open Access

    Supplementary Figure 1 from Phase IB/II Trial with Correlative Analyses of Doxorubicin plus Durvalumab Combination in Patients with Advanced Soft Tissue Sarcoma

    by Kum-Hee Yun, Nam Suk Sim, Su-Jin Shin, Young Han Lee, Wooyeol Baek, Yoon Dae Han, Ji Woo Park, Sang Kyum Kim, Iksung Cho, Inkyung Jung, et al.

  • Open Access

    Supplementary Table 3-4 from Phase IB/II Trial with Correlative Analyses of Doxorubicin plus Durvalumab Combination in Patients with Advanced Soft Tissue Sarcoma

    by Kum-Hee Yun, Nam Suk Sim, Su-Jin Shin, Young Han Lee, Wooyeol Baek, Yoon Dae Han, Ji Woo Park, Sang Kyum Kim, Iksung Cho, Inkyung Jung, et al.

  • Open Access

    Supplementary Table 1-2 from Phase IB/II Trial with Correlative Analyses of Doxorubicin plus Durvalumab Combination in Patients with Advanced Soft Tissue Sarcoma

    by Kum-Hee Yun, Nam Suk Sim, Su-Jin Shin, Young Han Lee, Wooyeol Baek, Yoon Dae Han, Ji Woo Park, Sang Kyum Kim, Iksung Cho, Inkyung Jung, et al.

  • Open Access

    Correction: A 3D Printed Poly(ε-caprolactone)-Collagen Hybrid Mesh (TissueDerm) for Breast Reconstruction after Mastectomy in a Pig Model

    by Kyu-Sik Shim, Han-Saem Jo, Shin Hyun Kim, Dohyun Kim, Yong-Kyu Park, Da-Hye Ryu, Won-Jai Lee, Tai-Suk Roh, Wooyeol Baek

  • Phase IB/II Trial with Correlative Analyses of Doxorubicin plus Durvalumab Combination in Patients with Advanced Soft Tissue Sarcoma

    by Kum-Hee Yun, Nam Suk Sim, Su-Jin Shin, Young Han Lee, Wooyeol Baek, Yoon Dae Han, Ji Woo Park, Sang Kyum Kim, Iksung Cho, Inkyung Jung, et al.

    Purpose: This open-label, phase IB/II study evaluated the efficacy and safety of standard-of-care doxorubicin combined with durvalumab [a programmed death 1 ligand (PD-L1) immune checkpoint inhibitor] in patients with advanced anthracycline-naïve soft tissue sarcoma (STS) and identified patients who would most likely benefit from this combination treatment. Patients and Methods: This trial (NCT03802071) included patients with metastatic and/or recurrent STS not previously treated with anthracycline or a PD-1/PD-L1 inhibitor. Phase IB assessed the safety and tolerability of doxorubicin [level 1 (75 mg/m2); level –1 (60 mg/m2)] in combination with durvalumab 1,500 mg once every 3 weeks until documented disease progression or unacceptable toxicity. Phase II evaluated treatment efficacy, with the primary endpoint being the objective response rate (ORR). Results: As no dose-limiting toxicities were observed during the phase IB trial (n = 3), the recommended phase II dose was 75 mg/m2 of doxorubicin. Of 41 evaluable patients, 1 (2.4%) achieved a complete response and 12 (29.3%) achieved a confirmed partial response, yielding an ORR of 31.7%. Median progression-free survival (PFS) was 7.6 months, and median overall survival was 23.8 months. The most common treatment-related grade 3 to 4 adverse events were neutropenia (n = 23, 53.4%), thrombocytopenia (n = 6, 13.9%), and anemia (n = 5, 11.6%). In prespecified exploratory correlative analyses, absence of RTK–RAS pathway genetic alterations [hazard ratio (HR), 6.446; 95% confidence interval (CI), 1.934–21.486; P = 0.002] and high PD-1 expression (HR, 0.214; 95% CI, 0.071–0.649; P = 0.006) were identified as independent predictors of longer PFS. Conclusions: Doxorubicin plus durvalumab combination therapy exhibited promising efficacy in advanced STS, with acceptable toxicity profile.

  • Open Access

    Anti-senescence Effects of Nanovesicles Derived from Cluster of Differentiation-146-Positive Tonsil Mesenchymal Stem Cells via Modulation of the Tumor Protein 53 Pathway

    by Dohyun Kim, Hong Bae Jeon, Kyu-Sik Shim, Jeong Su Park, Jeong-Kee Yoon, Jun Hee Lee, Jeong-Hui Park, Jang-Hyun Park, Jieun Kim, Jinseo Yoon, et al.

    Aging greatly contributes to the progressive dysfunction of tissues and organs that accompany the aging process. Recently, nanovesicles derived from tonsil mesenchymal stem cells (TMSC-NVs) were investigated for their potential to reverse cellular senescence. However, the molecular mechanisms through which TMSC-NVs prevent senescence remain unclear. In the present study, we focused on Cluster of Differentiation 146 (CD146), a surface marker used to identify specific MSC subgroups and examined the anti-senescence effects of CD146-positive TMSC-NVs (CD146 + TMSC-NVs). To evaluate the antisenescence effects of the CD146 + TMSC-NVs, passage-associated cellular senescence in vitro human dermal fibroblast model, ultraviolet-B-induced photoaging ex vivo model, and intrinsic aging in vivo mice model were assessed. Microarray analysis, immunofluorescence staining, and miRNA profiling demonstrated the anti-senescence mechanism of CD146 + TMSC-NVs through modulation of the p53 pathway, thereby effectively suppressing cellular senescence and matrix metalloproteinase activity and improving extracellular matrix remodeling. These results indicate the anti-senescence effects of CD146 + TMSC-NVs for therapeutic approach.

  • A 3D Printed Poly(ε-caprolactone)-Collagen Hybrid Mesh (TissueDerm) for Breast Reconstruction after Mastectomy in a Pig Model

    by Kyu-Sik Shim, Han-Saem Jo, Shin Hyun Kim, Dohyun Kim, Yong-Kyu Park, Da-Hye Ryu, Won-Jai Lee, Tai-Suk Roh, Wooyeol Baek

    Background: Implant supporting materials are currently used in breast reconstruction. However, when used in humans, they are associated with several problems. To address these issues, a new mesh called TissueDerm was created by combining a collagen sponge with a 3D printed polycaprolactone (PCL) mesh. It has shown promising results in pig experiments and could potentially replace the most commonly used acellular dermal matrix (ADM) for breast reconstruction. Methods: Four 12-month-old minipigs were used in this experiment. Silicone implants were wrapped with ADM or TissueDerm, and the breast tissue was excised and implanted along with the wrapped implants. Three months later, the minipigs were sacrificed and the skin and mammary gland tissue surrounding the implants were harvested for further analysis. Histological analyses and immunostaining were performed. Results: Although there was no significant difference in capsule thickness between the ADM and TissueDerm groups, collagen was more involved in TissueDerm, leading to better tissue regeneration. TissueDerm also induced lower levels of inflammatory markers TNF-α and IL-6 compared to ADM. However, capsules induced with ADM had significantly higher collagen fiber alignment and alpha-smooth muscle actin (α-SMA) positive immunoreactivity, suggesting that TissueDerm may be less likely to cause spherical contractures in the porcine model compared to ADM. Conclusions: The study found that TissueDerm has advantages over ADM in terms of easier tissue invasion and reduced spheroidization in a porcine model. The results showed that TissueDerm is a promising new mesh for implant-based breast reconstruction (IBBR) and could potentially replace ADM.